CAR-T

FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial
FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial
Endpoints
Cellectis
FDA
patient deaths
CAR-T
clinical trials
Multiple Myeloma
Flag link:
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
Flag link:
CRISPR stock slides as CAR-T death overshadows signs of efficacy
CRISPR stock slides as CAR-T death overshadows signs of efficacy
Fierce Biotech
CRISPR
CRISPR Therapeutics
CAR-T
patient deaths
Flag link:
EdiGene raises $67M to take gene-editing therapies into humans
EdiGene raises $67M to take gene-editing therapies into humans
Fierce Biotech
EdiGene
gene editing
CAR-T
beta thalassemia
ET-01
ET-02
Flag link:
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Fierce Biotech
Poseida Therapeutics
solid tumors
CAR-T
SEC
prostate cancer
Flag link:
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Fierce Biotech
JW Therapeutics
Juno Therapeutics
WuXi AppTech
IPOs
Hong Kong
CAR-T
Flag link:
Novartis says CAR-T cancer therapy works in second lymphoma type
Novartis says CAR-T cancer therapy works in second lymphoma type
BioPharma Dive
Novartis
Kymriah
follicular lymphoma
CAR-T
Flag link:
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Flag link:
Gilead’s Kite gains some height after second CAR-T approval in US
Gilead’s Kite gains some height after second CAR-T approval in US
Pharmaforum
Gilead Sciences
Kite Pharma
CAR-T
Flag link:
Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy
Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy
MedCity News
Gilead Sciences
CAR-T
KTE-X19
Tecartus
FDA
Kite Pharma
Flag link:
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold
Fierce Biotech
Cellectis
CAR-T
UCARCS1A
Multiple Myeloma
patient deaths
FDA
Flag link:
Bayer-backed Century buys Empirica to create brain cancer CAR-Ts
Bayer-backed Century buys Empirica to create brain cancer CAR-Ts
Fierce Biotech
Century Therapeutics
Empirica
cell therapies
brain cancer
glioblastoma
CAR-T
Flag link:
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
MedCity News
Sana Biotechnology
Juno Therapeutics
CAR-T
Flag link:
Poseida Therapeutics guns again for IPO
Poseida Therapeutics guns again for IPO
Fierce Biotech
Poseida Therapeutics
CAR-T
IPOs
Flag link:
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
Amsterdam
drug manufacturing
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
Fierce Biotech
Allogene
ASCO 2020
CAR-T
ALLO-501
ALLO-647
lymphoma
Flag link:
CMS proposes 1.6% inpatient increase and new CAR-T cell therapy payment
CMS proposes 1.6% inpatient increase and new CAR-T cell therapy payment
Healthcare Finance News
CMS
Medicare
CAR-T
cell therapy
Flag link:
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Fierce Biotech
Gilead Sciences
Kite Pharma
oNKo-innate
CAR-T
natural killer cell therapies
Flag link:
Calling Gilead's CAR-T infringement 'willful,' judge enhances BMS' award to $1.2B
Calling Gilead's CAR-T infringement 'willful,' judge enhances BMS' award to $1.2B
Fierce Pharma
Gilead Sciences
CAR-T
patents
Bristol-Myers Squibb
Flag link:

Pages